Literature DB >> 14598867

Dyslipidemia in patients with type 2 diabetes. relationships between lipids, kidney disease and cardiovascular disease.

Wendy P Battisti1, Joanne Palmisano, William E Keane.   

Abstract

Type 2 diabetes mellitus is a leading cause of morbidity and mortality. Cardiovascular disease (CVD) is the most prevalent complication and primarily accounts for the excess morbidity and mortality in diabetic patients, but microvascular complications, such as kidney disease and retinopathy, are frequent and contribute to the total disease burden. Lipid abnormalities in patients with type 2 diabetes are a major problem and associated with the increased risk of CVD. The most common pattern of dyslipidemia in these patients consists of elevated levels of triglycerides and low levels of high-density lipoprotein cholesterol. Low-density lipoprotein levels in these patients are often similar to that of the nondiabetic population, although there may be important qualitative differences in the pattern that contribute to the increased risk of CVD. Abnormal levels of urinary albumin occur in 30-40% of patients with type 2 diabetes and the presence of kidney disease enhances the mortality from CVD. Microalbuminuria, an early marker of diabetic nephropathy, is an independent risk factor for CVD. The increased levels of urinary albumin secretion may represent a more generalized vascular damage than renal microvascular injury alone. This Review focuses on the significance of diabetic dyslipidemia and microalbuminuria to CVD risk as well as to kidney complications. We also discuss the role of aggressive therapy to ameliorate vascular injury in the diabetic patient and reduce or prevent the cardiovascular and renal consequences of the disease.

Entities:  

Mesh:

Year:  2003        PMID: 14598867     DOI: 10.1515/CCLM.2003.181

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  13 in total

Review 1.  Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.

Authors:  Szu-chi Chen; Chin-Hsiao Tseng
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 2.  Cardiovascular disease risk in youth with diabetes mellitus.

Authors:  R Paul Wadwa
Journal:  Rev Endocr Metab Disord       Date:  2006-09       Impact factor: 6.514

3.  Prevalence of microalbuminuria and its risk factors in type 2 diabetic patients.

Authors:  M Afkhami-Ardekani; M Modarresi; E Amirchaghmaghi
Journal:  Indian J Nephrol       Date:  2008-07

4.  Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction.

Authors:  Marius Carstensen; Claus Thomsen; Ole Gotzsche; Jens Juul Holst; Jürgen Schrezenmeir; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2005-02-10

5.  Markers of cardiovascular risk in postmenopausal women with type 2 diabetes are improved by the daily consumption of almonds or sunflower kernels: a feeding study.

Authors:  Korina Richmond; Sheila Williams; Jim Mann; Rachel Brown; Alexandra Chisholm
Journal:  ISRN Nutr       Date:  2012-12-19

6.  Sex differences in the development of vascular and renal lesions in mice with a simultaneous deficiency of Apoe and the integrin chain Itga8.

Authors:  Ines Marek; Maurizio Canu; Nada Cordasic; Manfred Rauh; Gudrun Volkert; Fabian B Fahlbusch; Wolfgang Rascher; Karl F Hilgers; Andrea Hartner; Carlos Menendez-Castro
Journal:  Biol Sex Differ       Date:  2017-05-30       Impact factor: 5.027

Review 7.  Prevalence of diabetic nephropathy among Type 2 diabetic patients in some of the Arab countries.

Authors:  Abdulrhman Aldukhayel
Journal:  Int J Health Sci (Qassim)       Date:  2017 Jan-Mar

8.  Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-β1/Smad/miR-192 signaling pathway.

Authors:  Qian Mao; Cuicui Chen; Huankun Liang; Shuhai Zhong; Xinbo Cheng; Laiqing Li
Journal:  Exp Ther Med       Date:  2019-08-14       Impact factor: 2.447

9.  Lipid Metabolic Disorders and Ovarian Hyperstimulation Syndrome: A Retrospective Analysis.

Authors:  Feifei Liu; Qi Jiang; Xuedong Sun; Yuzhen Huang; Zhenzhen Zhang; Ting Han; Yuhua Shi
Journal:  Front Physiol       Date:  2020-11-19       Impact factor: 4.566

Review 10.  Pathophysiology of Type 2 Diabetes Mellitus.

Authors:  Unai Galicia-Garcia; Asier Benito-Vicente; Shifa Jebari; Asier Larrea-Sebal; Haziq Siddiqi; Kepa B Uribe; Helena Ostolaza; César Martín
Journal:  Int J Mol Sci       Date:  2020-08-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.